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Mathematical modelingGlioma differentiation therapy is a novel modality to increase anti-glioma effects using speciﬁc
drugs to induce glioma cell differentiation to glia-like cells. However, the molecular mechanisms
underlying glioma differentiation remain poorly understood. In this study, we built an
experiment-integrated mathematical model for glioma differentiation signaling pathways. Our
modeling and experimental analysis revealed that a ‘‘one-way-switch’’ bifurcation of cyclin D1
dynamics was critical for controlling the phenotypic transition of glioma cells. We also quantita-
tively evaluated drug combinations toward a synergistic therapeutic effect. These results provide
insights into the molecular mechanisms underlying glioma differentiation and implications for
the design of novel therapeutic targets in anti-cancer therapy.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Malignant gliomas are one of the most complex deadly cancers
worldwide. Traditional therapy with surgery, radiation, and
chemotherapy rarely cure the disease [1]. Differentiation therapy
is a novel promising strategy to increase anti-glioma effects using
speciﬁc agents to modify glioma cell differentiation [2]. Recent
reports have shown that cholera toxin (a type of biotoxin) can
induce glioma cell differentiation [3]. However, the molecular
mechanisms underlying glioma differentiation remain poorly
understood [4].
Our recent study showed that cholera toxin (CT), a well-known
inducer of cAMP activity [5], induced glioma cell differentiation.
Based on these observations, we hypothesized that cAMP/PKA sig-
naling played important roles in the induced differentiation of
glioma cells. Our experiment demonstrated that PKA-mediatedcAMP signaling phosphorylated CREB at Ser-133 [3], which was
required for cholera toxin-induced differentiation. cAMP/PKA sig-
naling can also inhibit the PI3K/AKT pathway that phosphorylates
GSK3b into its inactive form. The increased activation of GSK3b
also contributes to cholera toxin-induced differentiation [6].
GSK-3b has been shown to trigger cyclin D1 nuclear export and
its subsequent degradation [6], which is required for glioma cell
differentiation. Additionally, the IL-6/JAK2/STAT3 pathway was
demonstrated to be involved in cholera toxin-induced differentia-
tion of glioma cells [7].
To extend the analysis of interactions between drug stimulation
and glioma differentiation beyond a single linear pathway, we
designed a systems biology approach to study key components
and interactions involved in various signaling pathways that con-
trol phenotype switching of glioma cells between differentiation
and proliferation.
Several mathematical and computational models of cell fate
decision have been developed. Gérard et al. [8] proposed a compu-
tational model for the cyclin-dependent kinases (CDKs) network,
which controls the dynamics of the mammalian cell cycle, to inves-
tigate how the regulatory structure of the CDKs network results in
its temporal self-organization. Yao et al. [9] built an ordinary dif-
ferential equations (ODEs) model of the cyclin D/CDK-Rb–E2F
pathway and revealed a bistable switch of E2F that underlays
the restriction point, which is critical for the proliferation of
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experimentally. However, no models have been developed to
examine the regulatory mechanisms controlling the phenotype
transition of glioma cells between proliferation and differentiation.
In the present study, we used a systems biology approach to
investigate the molecular mechanisms controlling the differentia-
tion of glioma cells. First, we built an ODEs model of the signaling
pathways involved in drug-induced glioma differentiation.
Experimental data were used to ﬁt and validate the model. Then,
we performed sensitivity analysis and bifurcation analysis for the
developed system. The model analysis revealed that a
‘‘one-way-switch’’ bifurcation of cyclin D1 controlled the transition
of the glioma cell phenotype from proliferation to differentiation.
Moreover, the critical role of cyclin D1 in controlling glioma cell
phenotype switching was tested experimentally. We also dis-
cussed drug combinations toward a synergistic therapeutic effect.
These results provide insights into the molecular mechanisms
underlying glioma differentiation and suggest potential therapeu-
tic targets and the beneﬁt of combining drugs for glioma
chemotherapy.2. Results
2.1. Experiment-integrated mathematical modeling of the signaling
pathways involved in drug-induced glioma differentiation
Our previous experiments [3] showed that cholera toxin ele-
vated cAMP signaling in glioma cells and triggered morphologic
transformations in almost all glioma cells after treatment with
10 ng/ml cholera toxin for 48 h. Furthermore, a dose-dependent
effect of cholera toxin showed that GFAP expression increased
abruptly when the cholera toxin dose passed a threshold of
7.5–10 ng/ml. A steep rise in the response to increasing external
stimulation within a narrow range is characteristic of ‘‘ultrasensi
tivity’’ in the dose–response relationship [10,11]. The feature of
an all-or-none response and ultrasensitivity may characterize
bistability or a bifurcation switch [12,13]. We explored the mech-
anism underlying this interesting phenomenon by quantitatively
studying the drug-induced differentiation of signaling pathways
in glioma cells.
We modeled these signaling pathways by employing a set of
ODEs (Eqs. (2)–(12) in Section 4). Hill functions [14–16] were
employed to describe regulatory relationships between proteins
in the signaling pathways. As indicated in our previous experimen-
tal data (Table S1), cyclin D1 activation showed an ultrasensitive
response to cholera toxin treatment. Therefore, a non-linear
positive feedback of cyclin D1 activation (e.g., through cyclin D
auto-activation [21] or the cyclin D/CDK4-6/Rb/E2F/cyclin D
feedback loop [8,17]) was assumed in our mathematical model
(see details in Section 4). This assumption was also inspired by
parameter ﬁtting as described below.
The unknown parameters in the model were ﬁtted to the exper-
imental data [3,6,7] (Table S1) using an optimization procedure
(see Text S1 for detailed methods). Our data include both time ser-
ies data and different treatment condition data. A modiﬁed genetic
algorithm associated with an ODE solver was designed to integrate
and ﬁt these two types of data. The estimated parameter values are
listed in Table S2. Fig. 2 compares the simulation results with the
experimental data (mean squared error = 0.1384). The Pearson cor-
relation coefﬁcients were also calculated to quantify the closeness
between the simulated and experimental data, as shown in Fig. 2.
The complete results of parameter estimation are listed in Fig. S1.
These results demonstrated that the simulation results of the
model with the estimated parameters are consistent with the
experimental data. Moreover, we found that the model withoutfeedback of cyclin D1 did not ﬁt the experimental data well, which
demonstrated the rationality of the model assumption described
above.
We further validated the model with another sample of exper-
imental data [3,6]. Fig. 3 shows the experimental validation for
predicted GFAP and PCNA activation at different time points or
under different treatment conditions. Fig. 3A validates the dose
response of GFAP to cholera toxin (0, 5, 7.5 and 10 ng/ml);
Fig. 3B compares the time course of GFAP under treatment with
cholera toxin (10 ng/ml) on different days (days 0, 1, 2, 4 and 6)
using the experimental data. Validations of the GFAP and PCNA
levels under different conditions (GSK-3b gene silencing mediated
by siRNAs and cyclin D1 degradation inhibition using MG132) are
shown in Fig. 3C and D, respectively. The good agreement between
the simulations and experimental data conﬁrmed that our model
accurately reﬂected the dynamics of the signaling pathways and
thus could be used to predict the glioma cell’s states of differenti-
ation and/or proliferation.
We noted that the GFAP level showed a plateau and a subse-
quent sharp jump in response to increasing cholera toxin in the
range of 5–7.5 ng/ml (Fig. 3A). Therefore, we performed a more
detailed analysis of the dose response of GFAP to 5–7.5 ng/ml of
cholera toxin and the time course (0–48 h) to further understand
this interesting ‘‘running jump’’ phenomenon, as presented in
Fig. S2.2.2. Bifurcation of cyclin D1 controls the glioma cell’s phenotypic
transition from proliferation to differentiation
Sensitivity analysis was performed for the estimated parame-
ters (see Text S1 for detailed methods) to investigate which param-
eters in the model were more sensitive or critical during glioma
differentiation. In our analysis, the dose of cholera toxin was
increased from 10 to 100 ng/ml. In each case, each parameter
was increased by 1% from its estimated value; then, we obtained
the time-averaged percentage change of each variable value.
When the dose of cholera toxin was small (less than 10 ng/ml),
none of the sensitivity values were more than 5% (Fig. 4).
However, when the dose of cholera toxin was increased up to
100 ng/ml, some sensitivity values increased up to 10%, indicating
that the dynamic activation of some proteins in the signaling path-
ways changed dramatically. The sensitivity analysis result indi-
cated that the cAMP-increasing drugs could increase the kinetic
sensitivities of some proteins involved in the signaling pathways.
Moreover, cyclin D1-associated parameters were found to be more
sensitive in response to the increased drug doses compared to the
other parameters.
Next, we performed bifurcation analysis for cyclin D1 to inves-
tigate its dynamics. An irreversible ‘‘one-way switch’’ of decreased
cyclin D1 activation was revealed (Fig. 5). The cyclin D1 level was
high until the dose of cholera toxin exceeded a critical threshold
dose, at which point cyclin D1 decreased abruptly to a low value.
Then, the cyclin D1 remained low if the dose of cholera toxin
decreased rather than returning to a high level. When the dose of
cholera toxin was between 0 and the threshold, the cyclin D1 sig-
naling system was ‘‘bistable’’ [i.e., it had two stable steady-states
(the solid lines on the upper and lower branches) separated by
an unstable steady state (the dashed line on the intermediate
branch)]. The irreversible switch of cyclin D1 is consistent with
the proliferation inhibition feature of differentiated glia-like cells
induced by cholera toxin.
We investigated the function of cyclin D1 bifurcation in regulat-
ing cell phenotype switching by examining its correlations with
the differentiation marker GFAP and proliferation marker PCNA.
Fig. 6 shows the dose responses of cyclin D1, GFAP and PCNA
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Fig. 1. Drug-induced differentiation signaling pathways in glioma cells. cAMP/PKA signaling plays important roles in the differentiation of glioma cells, which can be elevated
by cholera toxin (CT; a type of biotoxin). PKA-mediated cAMP signaling can phosphorylate CREB at Ser-133 [3], which is required for cholera toxin-induced differentiation.
cAMP/PKA signaling can also inhibit the PI3K/AKT pathway that phosphorylates GSK3b into its inactive form. The increased activation of GSK3b also contributes to cholera
toxin-induced differentiation [6]. Furthermore, GSK-3b triggers cyclin D1 nuclear export and its subsequent degradation [6], which is required for differentiation in glioma
cells. The IL-6/JAK2/STAT3 pathway is also demonstrated to be involved in cholera toxin-induced differentiation of glioma cells [7]. GFAP and PCNA are reliable differentiation
and proliferation markers of glioma cells, respectively.
2306 X. Sun et al. / FEBS Letters 589 (2015) 2304–2311(evaluated at 48 h) to cholera toxin (0–10 ng/ml) and their tempo-
ral dynamics. The changes in GFAP and PCNA were closely corre-
lated with cyclin D1. The dynamic switch of cyclin D1 from ‘‘ON’’
(high level) to ‘‘OFF’’ (low level) triggered GFAP from low to high
and PCNA from high to low. These results demonstrated that cyclin
D1 might function as a ‘‘bio-switch’’ that controls glioma cell
phenotype switching between proliferation and differentiation.
2.3. Experimental validation
Experiments were performed to test the critical role of cyclin D1
in controlling differentiation and proliferation in glioma cancer
cells. RNA silencing of cyclin D1 was accomplished in C6 cells
(see Section 4). After treatment for 48 h, 3 fragments remarkably
reduced the level of cyclin D1 protein; the #3 fragment showed
the best silencing effect (Fig. 7A). After exposure to cyclin D1
siRNA for 48 h, the ﬂat polygonal shapes of C6 cells were trans-
formed into shrunken cell bodies (Fig. 7B) consistent with the
astrocyte-like shape induced by cholera toxin. To verify the domi-
nant role of cyclin D1 in controlling phenotype switching from pro-
liferation to differentiation in C6 cells, we evaluated the protein
expression of the differentiation marker GFAP and the proliferation
marker PCNA after cyclin D1 silencing. As shown in Fig. 7C, theGFAP protein was increased and PCNA was decreased when cyclin
D1 protein was decreased with a time line from 6 h to 48 h. Fig. 7D
demonstrates the dose responses of GFAP and PCNA to cyclin D1
siRNA at concentrations ranging from 12.5 to 100 nM. GFAP was
unltrasensitively induced by cyclin D1 siRNA at a concentration
between 0 and 12.5. The tendency of the PCNA protein level was
completely in step with cyclin D1, which showed good agreement
with the model prediction in Fig. 6. Full-length blots of
Fig. 7A, C and D were provided in Figs. S3 and S4, respectively.
2.4. Quantitative evaluation of the synergistic effects of drug
combinations
Currently, several inhibitors that target the signaling network
involved in this study are in clinical trials, including PI3K inhibitors
(e.g., LY294002 (LY), CAL-101, BKM120, and GDC-0941), STAT3
inhibitors (e.g., ISIS-STAT3Rx and OPB-31121) and cyclin D1 inhibi-
tors (e.g., Fascaplysin).
The inhibition effects of these inhibitors were incorporated into
our model by multiplying a type of inhibition Hill function into the
corresponding equations. Fig. 8 shows the dose responses of
combined CT&LY, CT&cyclin D1-inhibitor, and CT&STAT3-inhibitor
as well as the combination of the cyclin D1-inhibitor and
Fig. 2. Simulation results of activation levels of several proteins at different time points and/or under different conditions compared to experimental data. Conditions 1–7
correspond to different treatments (see Table S1). The mean squared error between the simulated data and experimental data is 0.1384. The Pearson correlation coefﬁcients
(r) were also calculated for each pair of simulated and experimental data to analyze the closeness between them.
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Fig. 3. Experimental validation for predicted GFAP and PCNA activation. (A) GFAP levels at different doses of cholera toxin (0, 5, 7.5 and 10 ng/ml); (B) GFAP levels under
treatment with cholera toxin (10 ng/ml) on different days (days 0, 1, 2, 4 and 6). (C) GFAP levels under different conditions (GSK-3b gene silencing mediated by siRNAs and
cyclin D1 degradation inhibition using MG132). (D) PCNA levels under different conditions involving interfering with cyclin D1 degradation using MG132.
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Fig. 4. Sensitivity analysis for the constructed system. Proteins 1–11 correspond to variables in Eqs. (2)–(12); parameters 1–39 were listed in Table S1. Each parameter was
increased by 1% from its estimated value; then, we obtained the time-averaged percentage change of each variable value. Increased doses of cholera toxin increased the
kinetic parameter sensitivities, especially for cyclin D1.
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Fig. 5. Bifurcation analysis of cyclin D1. Bifurcation diagram for cyclin D1 with
respect to doses of cholera toxin shows irreversible ‘‘one-way switch’’ of cyclin D1
activity.
2308 X. Sun et al. / FEBS Letters 589 (2015) 2304–2311STAT3-inhibitor. Among these combinations, the cyclin D1-inhibtor
and STAT3-inhibitor showed the most signiﬁcant anti-cancer effect
by promoting the differentiation and inhibiting the proliferation of
glioma cells.
To examine whether the combination of the cyclin D1-inhibtor
and STAT3-inhibitor had a synergistic effect, we adopted the Bliss
combination index [18,19] as follows:
CIBlissðx; yÞ ¼ R1ðxÞ þ R2ðyÞ  R1ðxÞR2ðyÞR12ðx; yÞ ; ð1ÞA 
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Fig. 6. Model prediction of glioma cell phenotype switching from proliferation to differ
dynamics of cyclin D1, GFAP and PCNA in response to cholera toxin (10 ng/ml). The simul
level) determined glioma cell phenotype switching from proliferation (high PCNA level)where RiðxÞ is the ratio of the normalized level of differentiation to
proliferation of glioma cells induced by the inhibitor or drug i.
R1ðxÞ þ R2ðyÞ  R1ðxÞR2ðyÞ in Eq. (1) is the expected response effect,
and R12ðx; yÞ is the actual combination effect. Hence, the index
evaluates the combination as a synergistic effect if CI < 1, antagonis-
tic if CI > 1, and otherwise is additive. The model predicted that the
combinations of the cyclin D1-inhibtor and STAT3-inhibitor
resulted in dose-dependent synergism (Fig. 9). The higher their
combined dosages, the more synergy they preserved.
3. Discussion
In this study, we adopted a systems biology approach to study
the molecular mechanisms underlying glioma differentiation
therapy. Our model successfully captured the key kinetics of the
signaling pathways using both time series data and different
treatment condition data. The sensitivity analysis demonstrated
that cyclin D1 was a critical component in the signaling networks,
and further bifurcation analysis revealed that a ‘‘one-way-switch’’
bifurcation of cyclin D1 controlled glioma cell phenotype switching
from proliferation to differentiation.
Many experimental studies [20] have shown that cyclin D1
serves as a switch to regulate the continuation of cell cycle pro-
gression [21]. Guided by experiments, in this study a data-driven
modeling approach revealed that cyclin D1 controlled the pheno-
type transition of glioma cells from proliferation to differentiation.
In ongoing work, we are further surveying the proteins that
up-regulate cyclin D1 expression or activation [22,23] in a detailed0 6 12 18 24 30 36 42 480
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Fig. 7. Experimental validation of the critical role of cyclin D1 dynamics in controlling phenotype switching from proliferation to differentiation. (A) Immunoblot of cyclin D1
protein levels after transfection with cyclin D1 siRNA for 48 h. Morphology (B) and immunoblot of the time course (C) and dose responses (D) of cyclin D1, GFAP and PCNA
levels in cyclin D1 knockdown cells.
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Fig. 8. Dose responses of drug combinations. Among these combinations, the cyclin D1-inhibtor and STAT3-inhibitor showed the highest anti-cancer effect by promoting the
differentiation and inhibiting the proliferation of glioma cells.
X. Sun et al. / FEBS Letters 589 (2015) 2304–2311 2309feedback loop. The identiﬁcation of these proteins would provide
us with a better understanding of the mechanisms of resistance
to cyclin D1 inhibition. Furthermore, these regulators could betargeted in combination with cyclin D1 inhibition therapy to
reduce drug resistance [24] and induce a synergistic therapeutic
effect.
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Fig. 9. Synergy evaluation of the cyclin D1-inhibtor and STAT3-inhibitor. The model
predicted that the combination of the cyclin D1-inhibtor and STAT3-inhibitor
performed dose-dependent synergism.
2310 X. Sun et al. / FEBS Letters 589 (2015) 2304–2311The signaling pathways of glioma differentiation induced by
agents in this study were constructed from the experimental
evidence established previously. The inference of the signaling
pathway or signaling network involved in glioma differentiation
from multi-omics data is a vital task but is beyond the scope of
this study. In future work, we will link the signaling pathways
inferred from the experimental data to the phenotype of cell
differentiation and proliferation and build a multiscale model
[25–27] incorporating the experimental data at both the molecular
and cellular level to evaluate drug synergism and optimize drug
doses [28,29].
In summary, we explored the ‘‘one-way switch’’ bifurcation of
cyclin D1 that controls phenotype switching from proliferation to
differentiation in glioma cancer cells through an integration of
experimental data and a mathematical model of the signaling
pathways involved in glioma differentiation.4. Materials and methods
4.1. RNA silencing of cyclin D1
siRNA fragments (Sigma, St. Louis, Mo, USA) targeting rat cyclin
D1 were used to deplete the expression of the corresponding
genes. C6 cells were transfected with cyclin D1 siRNA at the indi-
cated concentrations and times using the Lipofectamine™
RNAiMAX reagent (Invitrogen, Carlsbad, CA, USA). The efﬁciency
of knockdown was evaluated by western blotting using an
anti-cyclin D1 antibody (1:1000, Cell Signaling Technology,
Beverly, MA, USA)4.2. Western blot analysis
C6 cells were cultured in 35 mm plates. At 12 h after seeding,
the cells were treated with cyclin D1 siRNA at different concentra-
tions and times; then, total protein was extracted with M-PER
(Mammalian Protein Extraction Reagent, Pierce, Rockford, IL,
USA) according to the manufacturer’s instructions. After measure-
ment of the protein concentration with a BCA Protein Assay Kit
(Pierce, Rockford, IL, USA), equal amounts of protein samples were
combined with concentrated sodium dodecyl sulfate (SDS) loading
buffer, heated at 95 C for 5 min, and separated by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) prior toWestern blotting. Primary antibodies targeting cyclin D1
(1:1000), GPAP (1:1000), PCNA (1:5000, Cell Signaling
Technology, Beverly, MA, USA) and Tubulin (1:5000, Sigma) were
used in this study. After incubation with a horseradish
peroxidase-labeled secondary antibody (1:1000, Cell Signaling
Technology, Beverly, MA, USA), the visualization of protein was
accomplished with the enhanced chemiluminescence detection
system (Pierce, Rockford, IL, USA) and an immunoblotting imaging
and analysis system (BioRad, CA, USA).4.3. ODEs modeling
We used a system of ODEs to model the signaling pathways
induced by cholera toxin (shown in Fig. 1). Michaelis–Menten
kinetics and Hill functions were employed to describe regulatory
relationships within the signaling network given that the less
critical reaction details were simpliﬁed.
Cholera toxin induced-phosphorylation of PKA, CREB, PI3K, AKT
and GSK3b upstream of the signaling pathway was described by
the following Eqs. (2)–(6).
d½PKA
dt
¼ a1 þ V1  CT
n1
K1 þ CTn1
 d1½PKA ð2Þ
d½CREB
dt
¼ V2  ½PKA
K2 þ ½PKA  d2½CREB ð3Þ
d½PI3K
dt
¼ 1
1þ ½PKA=K3  d3½PI3K ð4Þ
d½AKT
dt
¼ V4  ½PI3K
K4 þ ½PI3K  d4½AKT ð5Þ
d½pGSK3b
dt
¼ V5  ð½GSK3bT   ½pGSK3bÞ
K5 þ ½GSK3bT   ½pGSK3b
 ½AKT  d5½pGSK3b ð6Þ
where Vi and Ki represent the maximal reaction rate and Michaelis
constant of each protein mediated by its upstream regulator,
respectively, and ni is a Hill coefﬁcient. a1 in Eq. (2) represents
the base activation rate of PKA by cAMP. pGSK3b in Eq. (6) indicates
the inactive, phosphorylated form of GSK3b, and ½GSK3bT  is total
GSK3b. Hence, the active, unphosphorylated form of GSK3b
½aGSK3b is formulized as
½aGSK3b ¼ ½GSK3bT   ½pGSK3b:
Active GSK3b can trigger cyclin D1 translocation and degrada-
tion; therefore, the degradation rate of cyclin D1 is dependent on
GSK3b as described in the following function,
f 1ð½aGSK3bÞ ¼ d6 
½aGSK3b
K6b þ ½aGSK3b  ½Cyclin D1:
Additionally, self-ampliﬁcation or a positive feedback loop was
assumed [8,17] for cyclin D1 to model its ultrasensitive response to
graded changes of cholera toxin doses as indicated in the experi-
mental data (Table S1). The self-ampliﬁcation was described by
the following non-linear Hill function,
f 2ð½Cyclin D1Þ ¼
V6  ½Cyclin D1n2
Kn26a þ ½Cyclin D1n2
:
Therefore, the change rate of cyclin D1 balanced by its activa-
tion and degradation was modeled as follows,
d½Cyclin D1
dt
¼ f 2ð½Cyclin D1Þ  f 1ð½aGSK3bÞ: ð7Þ
X. Sun et al. / FEBS Letters 589 (2015) 2304–2311 2311Similarly, cAMP-dependent activation of the IL6-JAK2-STAT3
pathway induced by cholera toxin was described using Hill func-
tions as below,
d½IL6
dt
¼ V7  ½cAMP
K7 þ ½cAMP  d7½IL6 ð8Þ
d½JAK2
dt
¼ V8  ½IL6
K8 þ ½IL6  d8½JAK2 ð9Þ
d½STAT3
dt
¼ V9  ½JAK2
K9 þ ½JAK2  d9½STAT3: ð10Þ
GFAP is a reliable marker of glioma cell differentiation, which is
dependent on the activation levels of CREB, STAT3 and active
GSK3b. Additionally, the degradation of cyclin D1 is a prerequisite
for the differentiation of glioma cells. We modeled the activation
level of GFAP as follows,
d½GFAP
dt
¼ f 3ð½Cyclin D1Þ
 V10ab  ½CREB
K10a þ ½CREB 
½STAT3
K10b þ ½STAT3 þ
V10c  ½aGSK3bn3
K10c þ ½aGSK3bn3
 !
 d10½GFAP:
ð11Þ
where
f 3ð½Cyclin D1Þ ¼
C  ½Cyclin D1
C
 þ
with C as the maximal value of the steady states of cyclin D1
and ðxÞþ ¼ x; x > 00; x 6 0

.
Similarly, PCNA activation by cyclin D1 and STAT3 through the
above pathways was modeled as
d½PCNA
dt
¼ V11a  ½Cyclin D1
K11a þ ½Cyclin D1 þ
V11b  ½STAT3
K11b þ ½STAT3  d11½PCNA: ð12Þ
The methods of parameter estimation and sensitivity analysis
were described in Text S1.
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